A pipeline of innovation
PTC is committed to developing clinically differentiated medicines that provide benefits to patients with rare disorders. This is the foundation that drives investment in a robust pipeline of transformative medicines and PTC’s mission to provide access to best-in-class treatments for patients who have an unmet medical need.
PTC’s research and development activity is based out of its laboratory facility in the US.
Approved Medicines
Please note that this information is not intended to replace the advice of a qualified healthcare professional.
Please click here to view the current Patient Information Leaflets (PIL) and Summary of Product Characteristics (SPC) for each of our licensed medicines.
For Medical Information please contact us as follows:
medinfo@ptcbio.com
Tel: (+353) 14475165
Reporting of side effects:
If you or the child you are caring for get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the national reporting system listed below. By reporting side effects, you can help provide more information on the safety of your medicine.
Please see the information below for how to report side effects.
Adverse events should be reported to the Pharmacovigilance Unit at the Health Products Regulatory Authority (HPRA) at: http://hpra.ie
Adverse events should also be reported to PTC on (+353) 14475165 or pharmacovigilance@ptcbio.com. or pharmacovigilance@ptcbio.com
Leveraging our expertise and cutting-edge biotechnology platforms, we’re urgently turning the latest scientific advances into purposeful treatments
We're committed to making progress in rare disease through clinical trial research, each and every moment of every day